Atomo Diagnostics: Receives new order for COVID-19 tests
- Atomo Diagnostics has received an unscheduled purchase order from French company NG Biotech to supply 422,000 COVID-19 blood test devices
- The rapid blood tests also used to detect the presence of COVID-19 antibodies, and can deliver results in just 15 minutes
- Atomo Co-Founder and Managing Director John Kelly says the added demand means the company also will have to increase production.
- Then the companies are now in talks about expanding the sales footprint for the tests in other territories
- Atomo currently ramping up production capacity, with the first phase scheduled to come online in July this year
- Atomo Diagnostics stocks have risen 7.9 per cent off the back of this morning’s announcement, with shares priced at 48 cents each
